TherapeuticsMD Inc. Common Stock (TXMD)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses whose cash flows I can understand and buy at a sensible price. TherapeuticsMD is a tiny royalty company with one employee, collecting income from women's health products such as IMVEXXY, BIJUVA, and ANNOVERA. The royalty model can be capital-light, but scale is minuscule. Filed revenue rose from $1.3 million in FY2023 to $1.8 million in FY2024 to $3.0 million in FY2025. Net loss narrowed from $10.3 million in FY2023 to $2.2 million in FY2024 to $569,000 in FY2025. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $724,000 and net income was $95,000. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $869,000 and net income was $155,000. That is real improvement. Free cash flow of $2.7 million and an 11.9% FCF yield, both FairStock calculations, against a $22.7 million market cap at the 2026-10-13 close, look interesting. FairStock's P/B calculation of 0.84 is also below one. But the P/E of -65.33, EPS of -$0.03, ROE of -1.08%, ROCE of -2.88%, and Altman Z-Score of -33.91 show fragility. Piotroski is 7/9, and debt-to-equity is 0.20, so not all bad. Still, a royalty stream on small products is no wide moat. The computed Lynch category is TURNAROUND, based on a loss in the latest year after earlier profits. FairStock Score is 52/100. At $1.96, with the 52-week range $1.03 to $2.95, I would demand a larger margin of safety and evidence that recent quarterly profits persist.

In plain English: TherapeuticsMD is a tiny healthcare company that earns fees from women's health products. Its sales have been growing and it recently made small profits, but it had a loss in its latest full year and the business is very small. At the 2026-10-13 close of $1.96, the stock looks not clearly cheap or expensive: it trades below its accounting value and produces some cash, but profits are thin and the balance sheet looks risky.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K/A (period ended 2025-12-31) · FY2024 10-K/A (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer